Psychiatric Disorders
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Oregon TherapeuticsFrance - Paris
1 program1
Genetically-guided treatment with FDA-approved psychotropic drugsPhase 41 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Oregon TherapeuticsGenetically-guided treatment with FDA-approved psychotropic drugs
Bristol Myers SquibbKarXT
Clinical Trials (2)
Total enrollment: 24 patients across 2 trials
Clinical Utility of Pharmacogenomics of Psychotropic Medications
Start: Jun 2019Est. completion: Jul 20210
Phase 4Withdrawn
Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders
Start: Apr 2025Est. completion: Jul 202524 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.